Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4933]

EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated CLL

EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated...

EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML

EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML

EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations

EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations

EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL

EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL

EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma significantly improves PFS

EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment...

$EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma$

EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory...

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Scientists discover a potential new marker to personalised therapy for breast cancer

Scientists discover a potential new marker to personalised therapy for breast cancer

Scientists increase the odds of identifying cancer-causing mutations before tumours take hold

Scientists increase the odds of identifying cancer-causing mutations before tumours take hold

Immunotherapy may play role in treating non-metastatic gastroesophageal cancer

Immunotherapy may play role in treating non-metastatic gastroesophageal cancer

More from ecancer